ArticleBrazilian journal of microbiology : [publication of the Brazilian Society for Microbiology]2026
Upstream endotoxin removal in recombinant protein purification: an optimised pre-cell disruption strategy for reducing endotoxin contamination of inclusion bodies in Escherichia coli.
Article in Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology], 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Endotoxin contamination remains a critical challenge in recombinant protein production using Gram-negative bacteria, particularly for intracellularly expressed, positively charged proteins prone to lipopolysaccharide (LPS) binding. This study introduces an efficient upstream strategy for LPS removal before the cell disruption, aimed at reducing the endotoxin contamination load in the downstream purification process. A recombinant cationic protein (named as 4mer-S3-DP) was expressed in Escherichia coli (E. coli) BL21 (DE3), and biomass was treated with varying concentrations and incubation times of Tris-HCl and EDTA, as defined by a central composite design (CCD) of response surface methodology (RSM). Endotoxin levels in inclusion bodies (IBs) were quantified using a chromogenic Limulus Amebocyte Lysate (LAL) assay, and statistical modelling was performed to optimize treatment conditions. The final quadratic model demonstrated high predictive accuracy, and response surface analysis revealed that both insufficient and excessive treatment conditions could increase endotoxin contamination. Optimal conditions, consisting of 70 mM Tris-HCl for 30 min and 60 mM EDTA for 5 min, achieved a 2.7-log reduction in endotoxin levels (99.8%) without compromising protein integrity, as confirmed by SDS-PAGE analysis. Experimental validation of the optimum criteria predicted by this model showed no significant difference between predicted and observed endotoxin levels of IBs. This upstream intervention as a simple and effective endotoxin removal approach before the cell lysis could be adaptable to other recombinant proteins expressed in Gram-negative bacterial.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.